Post-earnings recap
Reported
Mon, Feb 6, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a loss of $0.39 per share, which was significantly below expectations. The stock reacted negatively, dropping by 8.79%. The lack of revenue data and guidance further contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.39 | N/A | -134.21% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.